Pharmacokinetic (PK) interaction between epidoxorubicin (EPI) and docetaxel (TXT) in patients with metastatic breast cancer (MBC)

被引：1
|
作者：
Cattel, L
Airoldi, M
Brusa, P
Tagini, V
Recalenda, V
Marchionatti, S
Bumma, C
Pedani, F
机构：
[1] Univ Hosp Pharmacol, Turin, Italy
[2] Dept Oncol, Turin, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81734-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1318
引用
收藏
页码：S328 / S328
页数：1
相关论文
共 50 条
  • [21] Docetaxel toxicity and activity in anthracycline-pretreated metastatic breast cancer (MBC)
    Milella, M
    Vaccaro, A
    Ferraresi, V
    D'Ottavio, AM
    Papaldo, P
    Nisticò, C
    Marsella, A
    Thorel, MF
    Carpino, A
    Cercato, MC
    Terzoli, E
    Cognetti, F
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S42 - S42
  • [22] Low dose-intensity docetaxel (D) in pretreated patients (pts) with metastatic breast cancer (MBC).
    Massacesi, C
    Battelli, N
    Mazzanti, P
    Delprete, S
    Pilone, A
    Rossini, S
    Giustini, L
    Battelli, T
    ANNALS OF ONCOLOGY, 2000, 11 : 39 - 39
  • [23] A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC).
    Connolly, R. M.
    Rudek, M. A.
    Mc Leod, H. L.
    Garrett-Mayer, E.
    Jeter, S. C.
    Wright, L. A.
    Stearns, V.
    Armstrong, D. K.
    Fetting, J. H.
    Watkins, S. P.
    Davidson, N. E.
    Wolff, A. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)
    Guastalla, JP
    Bonneterre, J
    Fumoleau, P
    Piccart, M
    Tubiana, M
    Chevallier, B
    Nieamann, C
    Alakl, M
    Nichol, A
    Riva, A
    Marty, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 348 - 348
  • [25] A phase I trial of docetaxel every 21 days in elderly patients with metastatic breast cancer (MBC).
    Zanetta, S
    Albrand, G
    Bachelot, T
    Ardiet, CJ
    Tranchand, B
    Droz, JP
    ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [26] Jones fractures in patients with metastatic breast cancer (MBC)
    Van Poznak, C
    Boland, P
    Morris, C
    Dickler, M
    Hudis, C
    Healey, J
    BONE, 2006, 38 (03) : S85 - S85
  • [27] Chemotherapy in elderly patients with metastatic breast cancer (MBC)
    Wildiers, H.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S18 - S18
  • [28] Docetaxel (TXT), epirubicin (EPI) and raltitrexed (TOM) in advanced breast cancer (ABC), patients. A phase I study: our results.
    Simoncini, E
    Ferrari, V
    Marpicati, P
    Montini, E
    Rangoni, G
    Mambrini, A
    Pagani, M
    Vassalli, L
    Marini, G
    ANNALS OF ONCOLOGY, 2000, 11 : 27 - 27
  • [29] Pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib (ribo) in Black patients with metastatic breast cancer (mBC): The LEANORA study
    Smith, Donald
    Schlam, Ilana
    Peer, Cody
    Sissung, Tristan
    Schmidt, Keith Thomas
    Tan, Ming Tony
    Chitalia, Ami
    Bishopric, Nanette H.
    Steinberg, Seth M.
    Choo-Wosoba, Hyoyoung
    Gallagher, Christopher
    Ashai, Nadia
    Whitaker, Kristen Danielle
    Mainor, Candace Bavette
    Tiwari, Shruti Rakesh
    Swanson, Nicole
    Malloy, Stacy K.
    Isaacs, Claudine
    Figg, William Douglas
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer
    Wenzel, C
    Bartsch, R
    Locker, GJ
    Hussian, D
    Pluschnig, U
    Sevelda, U
    Gnant, MF
    Jakesz, R
    Zielinski, CC
    Steger, GG
    ANTI-CANCER DRUGS, 2005, 16 (04) : 441 - 445
12345